155 related articles for article (PubMed ID: 8013790)
21. The molecular signature of normal squamous esophageal epithelium identifies the presence of a field effect and can discriminate between patients with Barrett's esophagus and patients with Barrett's-associated adenocarcinoma.
Brabender J; Marjoram P; Lord RV; Metzger R; Salonga D; Vallböhmer D; Schäfer H; Danenberg KD; Danenberg PV; Selaru FM; Baldus SE; Hölscher AH; Meltzer SJ; Schneider PM
Cancer Epidemiol Biomarkers Prev; 2005 Sep; 14(9):2113-7. PubMed ID: 16172218
[TBL] [Abstract][Full Text] [Related]
22. Barrett's oesophagus: microsatellite analysis provides evidence to support the proposed metaplasia-dysplasia-carcinoma sequence.
Gleeson CM; Sloan JM; McGuigan JA; Ritchie AJ; Weber JL; Russell SE
Genes Chromosomes Cancer; 1998 Jan; 21(1):49-60. PubMed ID: 9443041
[TBL] [Abstract][Full Text] [Related]
23. P53 mutational status improves estimation of prognosis in patients with curatively resected adenocarcinoma in Barrett's esophagus.
Schneider PM; Stoeltzing O; Roth JA; Hoelscher AH; Wegerer S; Mizumoto S; Becker K; Dittler HJ; Fink U; Siewert JR
Clin Cancer Res; 2000 Aug; 6(8):3153-8. PubMed ID: 10955797
[TBL] [Abstract][Full Text] [Related]
24. p53 and neoplastic progression in Barrett's esophagus.
Reid BJ
Am J Gastroenterol; 2001 May; 96(5):1321-3. PubMed ID: 11374661
[No Abstract] [Full Text] [Related]
25. DNA abnormalities as marker of risk for progression of Barrett's esophagus to adenocarcinoma: image cytometric DNA analysis in formalin-fixed tissues.
Fang M; Lew E; Klein M; Sebo T; Su Y; Goyal R
Am J Gastroenterol; 2004 Oct; 99(10):1887-94. PubMed ID: 15447746
[TBL] [Abstract][Full Text] [Related]
26. Genetic alterations in Barrett's esophagus and esophageal adenocarcinoma.
Dinjens WN
Minerva Chir; 2002 Dec; 57(6):733-52. PubMed ID: 12592217
[TBL] [Abstract][Full Text] [Related]
27. [Clinical significance of p53 tumor suppressor gene mutations in adenocarcinoma in Barrett esophagus].
Schneider PM; Hölscher AH; Wegerer S; König U; Becker K; Siewert JR
Langenbecks Arch Chir Suppl Kongressbd; 1998; 115(Suppl I):495-9. PubMed ID: 14518305
[TBL] [Abstract][Full Text] [Related]
28. p53-mutant clones and field effects in Barrett's esophagus.
Prevo LJ; Sanchez CA; Galipeau PC; Reid BJ
Cancer Res; 1999 Oct; 59(19):4784-7. PubMed ID: 10519384
[TBL] [Abstract][Full Text] [Related]
29. p53 immunoreactivity in Barrett's metaplasia, dysplasia, and adenocarcinoma--a case report.
Kimura H; Konishi K; Kaji M; Maeda K; Yabushita K; Miwa A
Hepatogastroenterology; 2001; 48(42):1662-4. PubMed ID: 11813596
[TBL] [Abstract][Full Text] [Related]
30. The molecular biology of esophageal adenocarcinoma.
Koppert LB; Wijnhoven BP; van Dekken H; Tilanus HW; Dinjens WN
J Surg Oncol; 2005 Dec; 92(3):169-90. PubMed ID: 16299787
[TBL] [Abstract][Full Text] [Related]
31. Molecular genetic analysis of surveillance biopsy samples from Barrett's mucosa--significance of sampling.
Werther M; Saure C; Pahl R; Schorr F; Rüschoff J; Alles JU; Heinmöller E
Pathol Res Pract; 2008; 204(5):285-94. PubMed ID: 18337019
[TBL] [Abstract][Full Text] [Related]
32. Barrett's oesophagus and p53.
Levine DS
Lancet; 1994 Jul; 344(8917):212-3. PubMed ID: 7913153
[No Abstract] [Full Text] [Related]
33. Mutagen sensitivity and neoplastic progression in patients with Barrett's esophagus: a prospective analysis.
Chao DL; Maley CC; Wu X; Farrow DC; Galipeau PC; Sanchez CA; Paulson TG; Rabinovitch PS; Reid BJ; Spitz MR; Vaughan TL
Cancer Epidemiol Biomarkers Prev; 2006 Oct; 15(10):1935-40. PubMed ID: 17035402
[TBL] [Abstract][Full Text] [Related]
34. Genomic alterations in malignant transformation of Barrett's esophagus.
Riegman PH; Vissers KJ; Alers JC; Geelen E; Hop WC; Tilanus HW; van Dekken H
Cancer Res; 2001 Apr; 61(7):3164-70. PubMed ID: 11306503
[TBL] [Abstract][Full Text] [Related]
35. Short-segment Barrett's esophagus associated with high-grade dysplasia.
Morita K; Fujimori T; Ono Y; Masuyama H; Nakamura T; Terano A
J Gastroenterol; 2002; 37(12):1083-5. PubMed ID: 12522544
[No Abstract] [Full Text] [Related]
36. Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrett's esophagus: a case-control study.
Sikkema M; Kerkhof M; Steyerberg EW; Kusters JG; van Strien PM; Looman CW; van Dekken H; Siersema PD; Kuipers EJ
Am J Gastroenterol; 2009 Nov; 104(11):2673-80. PubMed ID: 19638963
[TBL] [Abstract][Full Text] [Related]
37. Serum selenium levels in relation to markers of neoplastic progression among persons with Barrett's esophagus.
Rudolph RE; Vaughan TL; Kristal AR; Blount PL; Levine DS; Galipeau PC; Prevo LJ; Sanchez CA; Rabinovitch PS; Reid BJ
J Natl Cancer Inst; 2003 May; 95(10):750-7. PubMed ID: 12759393
[TBL] [Abstract][Full Text] [Related]
38. Stepwise radical endoscopic resection of the complete Barrett's esophagus with early neoplasia successfully eradicates pre-existing genetic abnormalities.
Peters FP; Krishnadath KK; Rygiel AM; Curvers WL; Rosmolen WD; Fockens P; Ten Kate FJ; van Baal JW; Bergman JJ
Am J Gastroenterol; 2007 Sep; 102(9):1853-61. PubMed ID: 17509033
[TBL] [Abstract][Full Text] [Related]
39. Molecular genetic changes in metastatic primary Barrett's adenocarcinoma and related lymph node metastases: comparison with nonmetastatic Barrett's adenocarcinoma.
Walch AK; Zitzelsberger HF; Bink K; Hutzler P; Bruch J; Braselmann H; Aubele MM; Mueller J; Stein H; Siewert JR; Höfler H; Werner M
Mod Pathol; 2000 Jul; 13(7):814-24. PubMed ID: 10912943
[TBL] [Abstract][Full Text] [Related]
40. Barrett's oesophagus: from metaplasia to dysplasia and cancer.
Fléjou JF
Gut; 2005 Mar; 54 Suppl 1(Suppl 1):i6-12. PubMed ID: 15711008
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
